Compounds > delavirdine
Page last updated: 2024-08-16

delavirdine and zidovudine

delavirdine has been researched along with zidovudine in 71 studies

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's28 (39.44)18.2507
2000's14 (19.72)29.6817
2010's28 (39.44)24.3611
2020's1 (1.41)2.80

Authors

AuthorsStudies
Althaus, IW; Biles, C; Busso, M; Genin, MJ; Morge, RA; Resnick, L; Reusser, F; Romero, DL; Tarpley, WG; Thomas, RC1
Mao, C; Sudbeck, EA; Uckun, FM; Venkatachalam, TK1
Maher, D; Mao, C; Pendergrass, S; Tuel-Ahlgren, L; Uckun, FM; Venkatachalam, TK; Zhu, D2
Andricopulo, AD; Moda, TL; Montanari, CA1
Balzarini, J; Chen, FE; De Clercq, E; Pannecouque, C; Wang, YP1
Cao, Y; De Clercq, E; Liu, X; Pannecouque, C; Wang, Y; Zhan, P1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1
Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V1
De Clercq, E; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P1
Clercq, ED; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P; Zhu, J1
Antonsson, M; Bengtsson, O; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Jerndal, G; Wan, H; Winiwarter, S1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Fransen, S; Gupta, S; Huang, W; Paxinos, EE; Petropoulos, CJ; Stawiski, E1
Corbau, R; Fishburn, L; Irving, S; Knöchel, T; Martin, A; Mori, J; Mowbray, C; Panton, W; Perros, M; Phillips, C; Ringrose, H; Smith-Burchnell, C; Thornberry, A; Westby, M; Wood, A1
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H1
De Clercq, E; Ge, W; Jiang, Y; Li, Z; Liu, X; Pannecouque, C; Wu, J; Zhan, P; Zhang, J1
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, FE; Clercq, ED; Dai, HF; Gu, SX; He, QQ; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, FE; De Clercq, E; Gu, SX; He, QQ; Li, ZM; Ma, XD; Pannecouque, C; Yang, SQ1
Balzarini, J; Chen, X; De Clercq, E; Li, D; Li, X; Liu, H; Liu, X; Pannecouque, C; Wang, L; Zhan, P1
Chen, W; Chen, X; De Clercq, E; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P1
Briñón, MC; Daelemans, D; Dehaen, W; Leen, V; Madrid, M; Pannecouque, C; Ribone, SR1
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S1
Balzarini, J; Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yan, ZH1
Balzarini, J; Chen, X; De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Xie, Z; Zhan, P; Zhang, L; Zhao, T1
De Clercq, E; Li, Z; Liu, H; Liu, X; Pannecouque, C; Wang, J; Zhan, P1
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Huang, XY; Pannecouque, C; Wu, HQ; Yan, ZH1
Chen, FE; Chen, WX; De Clercq, E; He, QQ; Pannecouque, C; Piao, HR; Wu, HQ; Wu, Y; Yan, ZH1
Balzarini, J; Chen, F; Chen, W; De Clercq, E; Liu, Y; Meng, G; Pannecouque, C; Zheng, A1
Chen, FE; Chen, WX; Daelemans, D; De Clercq, E; He, QQ; Pannecouque, C; Wu, HQ; Yao, J1
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Buckheit, RW; Cushman, M; Hartman, TL; Hoshi, A; Okazaki, M; Pannecouque, C; Sakamoto, T; Takayama, J; Xuan, M1
Chen, W; Daelemans, D; De Clercq, E; Huang, B; Liu, X; Pannecouque, C; Yang, J; Zhan, P1
Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Kang, D; Li, Z; Liu, X; Lu, X; Pannecouque, C; Xu, H; Zhan, P; Zhang, H; Zhou, Z1
Gu, SX; Ju, XL; Li, TT; Lu, HH; Pannecouque, C; Xiao, T; Xue, P; Zhang, X; Zheng, XJ; Zhu, YY1
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H1
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Nottet, HS; Oteman, MH; Verhoef, J; Visser, MR1
Chong, KT; Hinshaw, RR; Pagano, PJ1
Arts, EJ; Gu, Z; Li, Z; Quan, Y; Wainberg, MA1
Gu, Z; Li, X; Parniak, MA; Quan, Y; Wainberg, MA1
Boyle, J; Chaitt, DG; Coleman, S; Cox, SR; Daenzer, CL; Davey, RT; Eastman, PS; Falloon, J; Freimuth, WW; Herpin, BR; Kovacs, JA; Lane, HC; Masur, H; Metcalf, JA; Polis, MA; Reed, GF; Walker, RE; Wathen, L1
Berrios, L; Cox, S; Demeter, LM; Dexter, A; Freimuth, W; Gerondelis, P; Meehan, PM; Morse, G; Reichman, RC1
Chong, KT; Pagano, PJ1
Chong, KT; Dueweke, TJ; Gorman, RR; Hinshaw, RR; Ho, DD; Markowitz, M; Mo, H; Pagano, PJ; Poppe, SM; Slade, DE; Tarpley, WG; Thaisrivongs, S1
Been-Tiktak, AM; Borleffs, JC; Boucher, CA; de Graaf, L; de Haas, CJ; Nottet, HS; Schuurman, R; Verhoef, J1
Balzarini, J; De Clercq, E; Kleim, JP; Pelemans, H; Riess, G; Roesner, M; Winkler, I1
Bellman, PC1
Saag, MS; Schooley, RT1
Been-Tiktak, AM; Borleffs, JC; Boucher, CA; Brun-Vezinet, F; Colebunders, R; Cooper, DA; Gatell, JM; Hawkins, DA; Hoy, JF; Johnson, MA; Joly, V; Jost, J; Kennedy, DH; Moroni, M; Mulder, JW; Parkin, JM; Staszewski, S; Stewart, GJ1
Bassett, R; Connick, E; Demeter, L; Fischl, M; Freimuth, W; Friedland, GH; Griffith, B; Hirsch, M; Hughes, M; Morse, G; Nevin, T; Pollard, R1
Temesgen, Z; Wright, AJ1
Koeplinger, KA; Padbury, GE; Raub, TJ; Zhao, Z1
Acosta, EP; Bassett, RL; Bell, D; Eron, JJ; Fife, K; Johnson, VA; Kuritzkes, DR; Marschner, IC; Martinez, A; Murphy, RL; Pettinelli, CB; Sommadossi, JP; Wood, K1
Bentwich, Z; Chiodo, F; Concia, E; de Cian, W; Freimuth, WW; Gatell, AJ; Greenwald, C; Hawkins, DA; Hirschel, B; Joly, V; Jost, J; Lazzarin, A; Love, WC; Moroni, M; Vetter, N; Wilkins, EG1
Smart, T; Torres, G1
Mascolini, M1
James, JS1
Anderson, S1
Cheng, J; Han, N; Liu, YN; Liu, ZY; Wei, HS; Zhang, FJ; Zhao, HX; Zhao, Y1
Cao, YL; Chen, H; Guo, Y; Li, SX1

Reviews

4 review(s) available for delavirdine and zidovudine

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Antiretroviral chemotherapy.
    Current clinical topics in infectious diseases, 1998, Volume: 18

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine

1998
Antiretrovirals.
    Mayo Clinic proceedings, 1999, Volume: 74, Issue:12

    Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine

1999

Trials

6 trial(s) available for delavirdine and zidovudine

ArticleYear
Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:7

    Topics: Adult; Anti-HIV Agents; Biological Availability; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indoles; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine

1996
Efficacy and safety of combination therapy with delavirdine and zidovudine: a European/Australian phase II trial.
    International journal of antimicrobial agents, 1999, Volume: 11, Issue:1

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine

1999
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
    Journal of acquired immune deficiency syndromes (1999), 1999, Aug-01, Volume: 21, Issue:4

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Safety; Zidovudine

1999
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    AIDS (London, England), 2000, Jul-28, Volume: 14, Issue:11

    Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delavirdine; Female; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Viral Load; Zidovudine

2000
Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
    Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:11

    Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Treatment Outcome; Zidovudine

2000
Delavirdine combination and viral load.
    AIDS treatment news, 1997, Oct-17, Issue:No 281

    Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine

1997

Other Studies

61 other study(ies) available for delavirdine and zidovudine

ArticleYear
Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
    Journal of medicinal chemistry, 1993, May-14, Volume: 36, Issue:10

    Topics: Antiviral Agents; Delavirdine; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Virus Replication

1993
Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
    Bioorganic & medicinal chemistry letters, 1999, Jun-07, Volume: 9, Issue:11

    Topics: Anti-HIV Agents; Delavirdine; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Models, Molecular; Nevirapine; Pyridines; Thiourea

1999
N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
    Bioorganic & medicinal chemistry letters, 1999, Sep-20, Volume: 9, Issue:18

    Topics: Aminopyridines; Anti-HIV Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Thiourea

1999
N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
    Bioorganic & medicinal chemistry letters, 1999, Dec-20, Volume: 9, Issue:24

    Topics: Anti-HIV Agents; Cells, Cultured; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Pyridines; Reverse Transcriptase Inhibitors; Thiourea; Virus Replication

1999
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2008, Apr-01, Volume: 16, Issue:7

    Topics: Alkylation; Cell Line; HIV-1; Humans; Methylation; Molecular Structure; Nucleosides; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfhydryl Compounds

2008
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Oct-15, Volume: 18, Issue:20

    Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Chemical; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiadiazoles; Virus Replication

2008
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors

2009
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:11

    Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship

2009
Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2009, Aug-15, Volume: 17, Issue:16

    Topics: Acetanilides; Anti-HIV Agents; Binding Sites; Computer Simulation; HIV Reverse Transcriptase; Humans; Imidazoles; Structure-Activity Relationship

2009
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
    Journal of medicinal chemistry, 2009, Oct-22, Volume: 52, Issue:20

    Topics: Animals; Blood-Brain Barrier; Brain; Extracellular Fluid; Humans; Linear Models; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley

2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
    Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3

    Topics:

2008
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5

    Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Virus Replication

2010
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10

    Topics: Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Nitriles; Pyrazoles; Reverse Transcriptase Inhibitors

2010
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3

    Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution

2011
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2011, Jul-15, Volume: 19, Issue:14

    Topics: Anti-HIV Agents; Cell Line, Tumor; Crystallography, X-Ray; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidinones; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship; Virus Replication

2011
Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2011, Sep-01, Volume: 19, Issue:17

    Topics: Aniline Compounds; Cell Line; Chlorine; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2011
Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2011, Dec-01, Volume: 19, Issue:23

    Topics: Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2011
Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2012, Volume: 53

    Topics: HIV Reverse Transcriptase; HIV-1; HIV-2; Models, Molecular; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism

2012
Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
    Bioorganic & medicinal chemistry, 2012, Sep-15, Volume: 20, Issue:18

    Topics: Acetanilides; Anti-HIV Agents; Cell Line; Dose-Response Relationship, Drug; Drug Design; HIV-1; Humans; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Structure-Activity Relationship; Virus Replication

2012
Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry letters, 2012, Dec-01, Volume: 22, Issue:23

    Topics: Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thioglycolates; Triazines

2012
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
    Bioorganic & medicinal chemistry, 2012, Dec-01, Volume: 20, Issue:23

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide

2012
Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2012, Volume: 58

    Topics: Anti-HIV Agents; Antineoplastic Agents; Benzene Derivatives; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured

2012
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Binding Sites; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrimidines; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2014, Jan-01, Volume: 22, Issue:1

    Topics: Aniline Compounds; Anti-HIV Agents; Drug Design; HIV-1; Humans; Models, Molecular; Piperidines; Structure-Activity Relationship

2014
Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
    European journal of medicinal chemistry, 2014, Apr-09, Volume: 76

    Topics: Cell Line; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Humans; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Pyridines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Virus Replication

2014
Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2014, Apr-15, Volume: 22, Issue:8

    Topics: Binding Sites; Cell Line; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry, 2014, Jun-15, Volume: 22, Issue:12

    Topics: Anti-HIV Agents; Benzamides; Cell Survival; Cells, Cultured; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Nitriles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured; Virus Replication

2014
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2014, Jul-23, Volume: 82

    Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Microbial Sensitivity Tests; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry, 2015, Feb-01, Volume: 23, Issue:3

    Topics: Anti-HIV Agents; Binding Sites; Cell Line; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2015
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Feb-15, Volume: 109

    Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2016
Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: Anti-HIV Agents; Drug Stability; Esters; HIV-1; Humans; Inhibitory Concentration 50; Methane; Models, Molecular; Reverse Transcriptase Inhibitors

2016
Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
    European journal of medicinal chemistry, 2016, Oct-04, Volume: 121

    Topics: Binding Sites; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; Molecular Docking Simulation; Protein Conformation; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Solubility; Structure-Activity Relationship; Water

2016
Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
    Journal of medicinal chemistry, 2016, 09-08, Volume: 59, Issue:17

    Topics: Animals; Anti-HIV Agents; Cell Line, Tumor; Drug Resistance, Viral; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Molecular Docking Simulation; Mutation; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thiophenes

2016
Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
    Bioorganic & medicinal chemistry, 2017, 04-15, Volume: 25, Issue:8

    Topics: Anti-HIV Agents; Carbon-13 Magnetic Resonance Spectroscopy; HIV-1; Molecular Docking Simulation; Proton Magnetic Resonance Spectroscopy; Pyrimidines; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization

2017
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles

2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors

2019
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Anti-human immunodeficiency virus type 1 activities of novel non-nucleoside reverse transcriptase inhibitors.
    The Journal of antimicrobial chemotherapy, 1994, Volume: 33, Issue:2

    Topics: Antiviral Agents; Delavirdine; Drug Resistance, Microbial; HIV-1; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine

1994
Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Leukocytes, Mononuclear; Piperazines; Reverse Transcriptase Inhibitors; Virus Replication; Zalcitabine; Zidovudine

1994
[A new AIDS drug in evaluation].
    Fortschritte der Medizin, 1993, Aug-30, Volume: 111, Issue:24

    Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Delavirdine; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; Zidovudine

1993
Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays.
    The Journal of biological chemistry, 1995, Dec-29, Volume: 270, Issue:52

    Topics: Cell-Free System; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; Drug Antagonism; Drug Synergism; HIV Reverse Transcriptase; HIV-1; Indoles; Nevirapine; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine

1995
Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.
    Journal of virology, 1996, Volume: 70, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antiviral Agents; Delavirdine; Deoxycytosine Nucleotides; Dideoxynucleotides; DNA; HIV Antibodies; HIV Reverse Transcriptase; Humans; Indoles; Mice; Neutralization Tests; Nevirapine; Peptide Chain Elongation, Translational; Piperazines; Pyridines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Thymine Nucleotides; Zidovudine

1996
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association, 1997, Feb-01, Volume: 14, Issue:2

    Topics: Adult; Anti-HIV Agents; Delavirdine; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phenotype; Piperazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine

1997
Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Antiviral research, 1997, Volume: 34, Issue:1

    Topics: Anti-HIV Agents; Cell Line; Delavirdine; Didanosine; DNA, Viral; HIV-1; Humans; Indoles; Piperazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zidovudine

1997
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
    Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Cells, Cultured; Delavirdine; Drug Combinations; Drug Evaluation, Preclinical; Drug Synergism; Genotype; HIV Protease Inhibitors; HIV-1; Humans; Indoles; Piperazines; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Virus Replication; Zidovudine

1997
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 1997, Dec-12, Volume: 39, Issue:1015

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine

1997
In-vitro selection of HIV-1 variants resistant to non-nucleoside reverse transcriptase inhibitors in monocyte-derived macrophages.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:6

    Topics: Amino Acid Sequence; Delavirdine; Drug Resistance, Microbial; HIV Reverse Transcriptase; HIV-1; Humans; Macrophages; Molecular Sequence Data; Monocytes; Piperazines; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Zidovudine

1997
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined
    Biochemical pharmacology, 1998, Mar-01, Volume: 55, Issue:5

    Topics: Anti-HIV Agents; Antiviral Agents; Benzodiazepines; Cell Line; Delavirdine; Drug Resistance, Microbial; Furans; HIV Reverse Transcriptase; HIV-1; Humans; Imidazoles; Lamivudine; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation; Nevirapine; Quinoxalines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Zidovudine

1998
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    AIDS (London, England), 1998, Jul-30, Volume: 12, Issue:11

    Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine

1998
Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium.
    Journal of pharmaceutical and biomedical analysis, 1999, Volume: 19, Issue:3-4

    Topics: Adult; Biological Transport; Blood Proteins; Cells, Cultured; Cryopreservation; Delavirdine; Dose-Response Relationship, Drug; Extracellular Space; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Male; Protein Binding; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tissue Distribution; Zidovudine

1999
Delaviridine and AZT combination tested in women.
    AIDS patient care and STDs, 1997, Volume: 11, Issue:4

    Topics: Anti-HIV Agents; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Zidovudine

1997
Antiviral roundup.
    GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies, 1996, Volume: 10, Issue:8

    Topics: CD4 Lymphocyte Count; Cohort Studies; Delavirdine; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Mutation; Piperazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Zidovudine

1996
FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
    AIDS treatment news, 1996, Dec-06, Issue:No 260

    Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; Didanosine; Disease Progression; Drug Approval; Drug Industry; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load; Zidovudine

1996
Delavirdine (Rescriptor) approved.
    AIDS treatment news, 1997, Apr-18, Issue:No 269

    Topics: Anti-HIV Agents; Delavirdine; Didanosine; Drug Approval; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indoles; Piperazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine

1997
New developments in women and AIDS research.
    Project Inform perspective, 1997, Issue:22

    Topics: AIDS-Related Opportunistic Infections; Delavirdine; Drug Therapy, Combination; Estrogens; Female; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Indoles; Infant; Infectious Disease Transmission, Vertical; Isoquinolines; Nelfinavir; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Sulfonic Acids; Zidovudine

1997
Drugs for HIV infection.
    The Medical letter on drugs and therapeutics, 2001, Nov-26, Volume: 43, Issue:1119

    Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine

2001
[HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy].
    Zhonghua yi xue za zhi, 2007, Dec-11, Volume: 87, Issue:46

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; China; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV-1; Humans; Mutation; Nevirapine; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Viral Load; Zidovudine

2007
[Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2009, Volume: 44, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Delavirdine; Drug Evaluation, Preclinical; Drug Resistance, Viral; Genetic Vectors; HIV Reverse Transcriptase; HIV-1; Humans; Membrane Glycoproteins; Nevirapine; Plasmids; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Transfection; Viral Envelope Proteins; Virion; Virus Replication; Zidovudine

2009